Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Tamás Tábi, Éva Szökő, László Vécsei & Kálmán Magyar. (2013) The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease. Expert Opinion on Drug Metabolism & Toxicology 9:5, pages 629-636.
Read now
Read now
F. MUSSHOFF. (2000) ILLEGAL OR LEGITIMATE USE? PRECURSOR COMPOUNDS TO AMPHETAMINE AND METHAMPHETAMINE. Drug Metabolism Reviews 32:1, pages 15-44.
Read now
Read now
M. Strolin-Benedetti, G. Brogin, M. Bani, F. Oesch & J. G. Hengstler. (1999) Association of cytochrome P450 induction with oxidative stress in vivo as evidenced by 3-hydroxylation of salicylate. Xenobiotica 29:11, pages 1171-1180.
Read now
Read now
J. W. Gorrod & A. Raman. (1989) Mines as Intermediates in Oxidative Aralkylamine Metabolism. Drug Metabolism Reviews 20:2-4, pages 307-339.
Read now
Read now
Takemi Yoshida, Takiko Oguro & Yukio Kuroiwa. (1987) Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences. Xenobiotica 17:8, pages 957-963.
Read now
Read now
Articles from other publishers (76)
Jagadeesh Babu Thentu, Gopinadh Bhyrapuneni, Nagasurya Prakash Padala, Prathyusha Chunduru, Hanumanth Rao Pantangi & Ramakrishna Nirogi. (2021) Evaluation of monoamine oxidase A and B type enzyme occupancy using non-radiolabelled tracers in rat brain. Neurochemistry International 145, pages 105006.
Crossref
Crossref
Sharon L. Crowell‐Davis, Thomas F. Murray & Leticia Mattos DantasLeticia Mattos de Souza Dantas & Sharon L. Crowell‐Davis. 2019. Veterinary Psychopharmacology. Veterinary Psychopharmacology
185
199
.
Keith F. Tipton. (2018) 90 years of monoamine oxidase: some progress and some confusion. Journal of Neural Transmission 125:11, pages 1519-1551.
Crossref
Crossref
Christoffer Bundgaard, Liliana P. Montezinho, Neil Anderson, Christian Thomsen & Arne M?rk. (2016) Selegiline induces a wake promoting effect in rats which is related to formation of its active metabolites. Pharmacology Biochemistry and Behavior 150-151, pages 147-152.
Crossref
Crossref
Sangram Nag, Patrik Fazio, Lutz Lehmann, Georg Kettschau, Tobias Heinrich, Andrea Thiele, Marie Svedberg, Nahid Amini, Samira Leesch, Ana M. Catafau, Jonas Hannestad, Andrea Varrone & Christer Halldin. (2016)
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand,
18
F-Labeled Deuterated Fluorodeprenyl
. Journal of Nuclear Medicine 57:2, pages 315-320.
Crossref
Crossref
Kornélia Tekes, Zita Pöstényi, Erzsébet B. Faigl, Kálmán Magyar, András Polyák, György Trencsényi, Lajos Balogh & Huba Kalász. (2015) Distribution of N-methyl-14C-labeled selegiline in the rat. Journal of Pharmaceutical and Biomedical Analysis 111, pages 147-152.
Crossref
Crossref
Kan Zhong. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
3
.
Alex Rajput, Theresa Zesiewicz & Robert Hauser. 2013. Handbook of Parkinson's Disease, Fifth Edition. Handbook of Parkinson's Disease, Fifth Edition
430
447
.
Alex Rajput, Theresa Zesiewicz & Robert A. Hauser. 2013. Handbook of Parkinson’s Disease. Handbook of Parkinson’s Disease
430
447
.
Massimo Valoti, Marisa Costanzo, Gian Pietro Sgaragli, Virgili PerezEldiberto Fernandez-Alvarez & Mercedes Unzeta. (1994)
Interactions of Monoamine Oxidase Inhibitors,
N
-Acetylenic Analogues of Tryptamine, with Rat Liver Microsomal Cytochrome P450
. Journal of Pharmacy and Pharmacology 46:5, pages 360-365.
Crossref
Crossref
Orly WeinrebOrit Bar-AmKsenia ProsolovichTamar AmitMoussa B.H. Youdim. (2011) Does 1-(R)-aminoindan Possess Neuroprotective Properties Against Experimental Parkinson's Disease?. Antioxidants & Redox Signaling 14:5, pages 767-775.
Crossref
Crossref
K. Magyar, B. Szende, V. Jenei, T. Tábi, M. Pálfi & É. Szökő. (2010) R-Deprenyl: Pharmacological Spectrum of its Activity. Neurochemical Research 35:12, pages 1922-1932.
Crossref
Crossref
Orit Bar-Am, Orly Weinreb, Tamar Amit & Moussa B. H. Youdim. (2010)
The neuroprotective mechanism of 1-(
R
)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
. Journal of Neurochemistry 112:5, pages 1131-1137.
Crossref
Crossref
Orly Weinreb, Tamar Amit, Yotam Sagi, Noam Drigues & Moussa B. H. Youdim. (2009) Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain. Journal of Neural Transmission 116:11, pages 1457-1472.
Crossref
Crossref
Géza Szilágyi, László Simon, Edina Wappler, Kálmán Magyar & Zoltán Nagy. (2009) (−)Deprenyl-N-oxide, a (−)deprenyl metabolite, is cytoprotective after hypoxic injury in PC12 cells, or after transient brain ischemia in gerbils. Journal of the Neurological Sciences 283:1-2, pages 182-186.
Crossref
Crossref
Erin M. MacKenzie, Afshin Fassihi, Asghar Davood, Qiao-Hong Chen, Gillian Rauw, Gail Rauw, Edward E. Knaus & Glen B. Baker. (2008) N-Propynyl analogs of β-phenylethylidenehydrazines: Synthesis and evaluation of effects on glycine, GABA, and monoamine oxidase. Bioorganic & Medicinal Chemistry 16:17, pages 8254-8263.
Crossref
Crossref
K. Magyar, M. Pálfi, V. Jenei & É. Szökő. 2006. Oxidative Stress and Neuroprotection. Oxidative Stress and Neuroprotection
143
156
.
Sharon Crowell‐Davis & Thomas Murray. 2005. Veterinary Psychopharmacology. Veterinary Psychopharmacology
134
147
.
Sheng-Meng Wang, Ting-Cheng Wang & Yun-Seng Giang. (2005) Simultaneous determination of amphetamine and methamphetamine enantiomers in urine by simultaneous liquid–liquid extraction and diastereomeric derivatization followed by gas chromatographic–isotope dilution mass spectrometry. Journal of Chromatography B 816:1-2, pages 131-143.
Crossref
Crossref
Ferenc Lévai, Erzsébet Fejér, Gábor Szeleczky, Anna Szabó, Tünde Erős-Takácsy, Félix Hajdu, Gyula Szebeni, István Szatmári & István Hermecz. (2004) In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog. European Journal of Drug Metabolism and Pharmacokinetics 29:3, pages 169-178.
Crossref
Crossref
Matthias D'hooghe, Willem Van Brabandt & Norbert De Kimpe. (2004) New Synthesis of Propargylic Amines from 2-(Bromomethyl)aziridines. Intermediacy of 3-Bromoazetidinium Salts. The Journal of Organic Chemistry 69:8, pages 2703-2710.
Crossref
Crossref
Jarmo S. Salonen, Leena Nyman, Alan R. Boobis, Robert J. Edwards, Patricia Watts, Brian G. Lake, Roger J. Price, Anthony B. Renwick, Maria-José Gómez-Lechón, José V. Castell, Magnus Ingelman-Sundberg, Mats Hidestrand, Andre Guillouzo, Laurent Corcos, Peter S. Goldfarb, David F.V. Lewis, Päivi Taavitsainen & Olavi Pelkonen. (2003) COMPARATIVE STUDIES ON THE CYTOCHROME P450-ASSOCIATED METABOLISM AND INTERACTION POTENTIAL OF SELEGILINE BETWEEN HUMAN LIVER-DERIVED IN VITRO SYSTEMS. Drug Metabolism and Disposition 31:9, pages 1093-1102.
Crossref
Crossref
Ju-Tsung Liu & Ray H. Liu. (2002) Enantiomeric composition of abused amine drugs: chromatographic methods of analysis and data interpretation. Journal of Biochemical and Biophysical Methods 54:1-3, pages 115-146.
Crossref
Crossref
Kenichi Kitani, Chiyoko Minami, Ken-ichi Isobe, Kayoko Maehara, Setsuko Kanai, Gwen O. Ivy & Maria-Christina Carrillo. (2002) Why (−)deprenyl prolongs survivals of experimental animals: Increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mechanisms of Ageing and Development 123:8, pages 1087-1100.
Crossref
Crossref
Srinivasan ThyagaRajan & David L. Felten. (2002) Modulation of neuroendocrine–immune signaling by l-deprenyl and l-desmethyldeprenyl in aging and mammary cancer. Mechanisms of Ageing and Development 123:8, pages 1065-1079.
Crossref
Crossref
Takahiro Kamada, Toshio Chow, Toyoko Hiroi, Susumu Imaoka, Kazuhiko Morimoto, Hironori Ohde & Yoshihiko Funae. (2002) Metabolism of Selegiline Hydrochloride, a Selective Monoamine B-type Inhibitor, in Human Liver Microsomes. Drug Metabolism and Pharmacokinetics 17:3, pages 199-206.
Crossref
Crossref
E. Kwan, G.B. Baker, A. Shuaib, L. Ling & K.G. Todd. (2001) N‐methyl,N‐propargyl‐2‐phenylethylamine (MPPE), an analog of deprenyl, increases neuronal cell survival in thiamin deficiency encephalopathy. Drug Development Research 51:4, pages 244-252.
Crossref
Crossref
S ThyagaRajan, K.S Madden, S.Y Stevens & D.L Felten. (2000) Restoration of splenic noradrenergic nerve fibers and immune reactivity in old F344 rats: a comparison between L-deprenyl and L-desmethyldeprenyl. International Journal of Immunopharmacology 22:7, pages 523-536.
Crossref
Crossref
Trevor Archer & Anders Fredriksson. (2000) Restoration and putative protection in parkinsonism. Neurotoxicity Research 2:2-3, pages 251-292.
Crossref
Crossref
Massimo Valoti, Fabio Fusi, Maria Frosini, Federica Pessina, Keith F Tipton & Gian P Sgaragli. (2000) Cytochrome P450-dependent n-dealkylation of l-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, β-naphthoflavone and l-deprenyl. European Journal of Pharmacology 391:3, pages 199-206.
Crossref
Crossref
É. Szökõ, H. Kalász & K. Magyar. (1999) Biotransformation of deprenyl enantiomers. European Journal of Drug Metabolism and Pharmacokinetics 24:4, pages 315-319.
Crossref
Crossref
Paul Cumming, Fuji Yokoi, Anjing Chen, Paul Deep, Alain Dagher, David Reutens, Flavio Kapczinski, Dean F. Wong & Albert Gjedde. (1999) Pharmacokinetics of radiotracers in human plasma during positron emission tomography. Synapse 34:2, pages 124-134.
Crossref
Crossref
G. B. Baker, L. J. Urichuk, K. F. McKenna & S. H. Kennedy. (1999) Metabolism of Monoamine Oxidase Inhibitors. Cellular and Molecular Neurobiology 19:3, pages 411-426.
Crossref
Crossref
Andrew Siderowf & Roger Kurlan. (1999) MONOAMINE OXIDASE AND CATECHOL- O-METHYLTRANSFERASE INHIBITORS. Medical Clinics of North America 83:2, pages 445-467.
Crossref
Crossref
Iftekhar Mahmood. (1998) Is 10 Milligrams Selegiline Essential as an Adjunct Therapy for the Symptomatic Treatment of Parkinson's Disease?. Therapeutic Drug Monitoring 20:6, pages 717-721.
Crossref
Crossref
Harry Scheinin, Markku Anttila, Marja-Liisa Dahl, Hari Karnani, Leena Nyman, Päivi Taavitsainen, Olavi Pelkonen & Leif Bertilsson. (1998) CYP2D6 polymorphism is not crucial for the disposition of selegiline*. Clinical Pharmacology & Therapeutics 64:4, pages 402-411.
Crossref
Crossref
H. Kalász, Mária Báthori & E. Tyihák. (1998) Formaldehyde Generation by N-Demethylation. Acta Biologica Hungarica 49:2-4, pages 339-344.
Crossref
Crossref
ZS. Tarjányi, H. Kalász, I. Hollósi, M Báthori, T. Bartók, J. Lengyel, K. Maguar & S. Fürst. (1998) Chromatographic investigation and computer simulation of L-deprenyl metabolism. European Journal of Drug Metabolism and Pharmacokinetics 23:2, pages 324-328.
Crossref
Crossref
Qize Wei, Octavian P. Jurma & Julie K. Andersen. (1997) Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells. Journal of Neuroscience Research 50:4, pages 618-626.
Crossref
Crossref
Alan A. Boulton, Bruce A. Davis, David A. Durden, Lillian E. Dyck, Augusto V. Juorio, Xin-Min Li, I. Alick Paterson & Peter H. Yu. (1997) Aliphatic propargylamines: New antiapoptotic drugs. Drug Development Research 42:3-4, pages 150-156.
Crossref
Crossref
Robert A. Hauser & Theresa A. Zesiewicz. (2004) Sertraline for the treatment of depression in parkinson's disease. Movement Disorders 12:5, pages 756-759.
Crossref
Crossref
Esa H. Heinonen, Markku I. Anttila, Hari L. Karnani, Leena M. Nyman, Jouni A. Vuorinen, Kaija A. Pyykkö & Risto A. S. Lammintausta. (2013) Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans. The Journal of Clinical Pharmacology 37:7, pages 602-609.
Crossref
Crossref
Hannele Lahtinen, Jari Koistinaho, Risto Kauppinen, Antti Haapalinna, Riitta Keinänen & Juhani Sivenius. (1997) Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus. Brain Research 757:2, pages 260-267.
Crossref
Crossref
Julia Timár, Zsuzsanna Gyarmati, László Barna & Bertha Knoll. (1996) Differences in some behavioural effects of deprenyl and amphetamine enantiomers in rats. Physiology & Behavior 60:2, pages 581-587.
Crossref
Crossref
Elizabeth Head, Joanne Hartley, Anne Marie Kameka, Rick Mehta, Gwen O. Ivy, William W. Ruehl & Norton W. Milgram. (1996) The effects of L-deprenyl on spatial short term memory in young and aged dogs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 20:3, pages 515-530.
Crossref
Crossref
Iftekhar Mahmood, Jacqueline S. Marinac, Sandra Willsie & William D. Mason. (2006) Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharmaceutics & Drug Disposition 16:7, pages 535-545.
Crossref
Crossref
S. Kaakkola, H. Teräväinen, S. Ahtila, M. Karlsson, T. Naukkarinen, H. Rita & A. Gordin. (2011) Entacapone in combination with standard or controlled‐release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. European Journal of Neurology 2:4, pages 341-347.
Crossref
Crossref
Kathleen A. Haberny, Sharon L. Walsh, David H. Ginn, Jeffery N. Wilkins, Jane E. Garner, David Setoda & George E. Bigelow. (1995) Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug and Alcohol Dependence 39:1, pages 55-62.
Crossref
Crossref
N.W Milgram, G.O Ivy, M.P Murphy, E Head, P.H Wu, W.W Ruehl, P.H Yu, D.A Durden, B.A Davis & A.A Boulton. (1995) Effects of chronic oral administration of l-deprenyl in the dog. Pharmacology Biochemistry and Behavior 51:2-3, pages 421-428.
Crossref
Crossref
A. Fredriksson & T. Archer. (1995) Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice. Journal of Neural Transmission 102:1, pages 19-34.
Crossref
Crossref
Iftekhar Mahmood, David K. Peters & William D. Mason. (2006) The pharmacokinetics and absolute bioavailability of selegiline in the dog. Biopharmaceutics & Drug Disposition 15:8, pages 653-664.
Crossref
Crossref
Iftekhar Mahmood, Steven H. Neau & William D. Mason. (1994) An enzymatic assay for the MAO-B inhibitor selegiline in plasma. Journal of Pharmaceutical and Biomedical Analysis 12:7, pages 895-899.
Crossref
Crossref
KENICHI KITANI, SETSUKO KANAI, MARIA CRISTINA CARRILLO & GWEN O. IVY. (1994) (-)Deprenyl Increases the Life Span as Well as Activities of Superoxide Dismutase and Catalase but Not of Glutathione Peroxidase in Selective Brain Regions in Fischer Rats. Annals of the New York Academy of Sciences 717:1, pages 60-71.
Crossref
Crossref
R. La Croix, E. Pianezzola & M. Strolin Benedetti. (1994) Sensitive high-performance liquid chromatographic method for the determination of the three main metabolites of selegiline (l-deprenyl) in human plasma. Journal of Chromatography B: Biomedical Sciences and Applications 656:1, pages 251-258.
Crossref
Crossref
J. Fang & P.H. Yu. (1994) Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 33:6, pages 763-768.
Crossref
Crossref
Douglas L. Gelowitz, J. Steven Richardson, Thomas B. Wishart, Peter H. Yu & Chien-Tsai Lai. (1994) Chronic L-deprenyl or L-amphetamine: Equal cognitive enhancement, unequal MAO inhibition. Pharmacology Biochemistry and Behavior 47:1, pages 41-45.
Crossref
Crossref
M. P. Murphy, P. H. Wu, N. W. Milgram & G. O. Ivy. (1993) Monoamine oxidase inhibition byl-deprenyl depends on both sex and route of administration in the rat. Neurochemical Research 18:12, pages 1299-1304.
Crossref
Crossref
N. W. Milgram, G. O. Ivy, E. Head, M. P. Murphy, P. H. Wu, W. W. Ruehl, P. H. Yu, D. A. Durden, B. A. Davis, I. A. Paterson & A. A. Boulton. (1993) The effect ofl-deprenyl on behavior, cognitive function, and biogenic amines in the dog. Neurochemical Research 18:12, pages 1211-1219.
Crossref
Crossref
Mark L. J. Reimer, Orval A. Mamer, A. Paul Zavitsanos, A. Waheed Siddiqui & D. Dadgar. (1993) Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biological Mass Spectrometry 22:4, pages 235-242.
Crossref
Crossref
George T. Barthalmus, Laura K. Hardin & David Thompson. (1993) MAO-A and -B inhibitors selectivity alter Xenopus mucus-induced behaviors of snakes. Pharmacology Biochemistry and Behavior 44:2, pages 321-327.
Crossref
Crossref
M.C. Carrillo, S. Kanai, Y. Sato, M. Nokubo, G.O. Ivy & K. Kitani. (1993) The optimal dosage of (−)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sciences 52:24, pages 1925-1934.
Crossref
Crossref
E. H. Heinonen, M. I. Anttila & R. A. S. Lammintausta. 1993. Inhibitors of Monoamine Oxidase B. Inhibitors of Monoamine Oxidase B
201
213
.
Kennerly S. Patrick, Bich Lan Nguyen & J. David McCallister. (1992) Gas chromatographic—mass spectrometric determination of plasma selegiline using a deuterated internal standard. Journal of Chromatography B: Biomedical Sciences and Applications 583:2, pages 254-258.
Crossref
Crossref
E. Head & N.W. Milgram. (1992) Changes in spontaneous behavior in the dog following oral administration of L-deprenyl. Pharmacology Biochemistry and Behavior 43:3, pages 749-757.
Crossref
Crossref
H. O. Borbe & G. Peter. 1992. Biologische Psychiatrie. Biologische Psychiatrie
226
232
.
E. H. Heinonen & R. Lammintausta. (1991) A review of the pharmacology of selegiline. Acta Neurologica Scandinavica 84:S136, pages 44-59.
Crossref
Crossref
Jarmo S. Salonen. (1990) Determination of the amine metabolites of selegiline in biological fluids by capillary gas chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 527, pages 163-168.
Crossref
Crossref
H. O. Borbe, G. Niebch & B. Nickel. 1990. Amine Oxidases and Their Impact on Neurobiology. Amine Oxidases and Their Impact on Neurobiology
131
137
.
Karl-Heinz BeyerKarl-Heinz Beyer. 1990. Biotransformation der Arzneimittel. Biotransformation der Arzneimittel
500
501
.
Heinonen E H, Myllylä V, Sotaniemi K, Lammintausta R, Salonen J S, Anttila M, Savijärvi M, Kotila M & Rinne U K. (1989) Pharmacokinetics and metabolism of selegiline. Acta Neurologica Scandinavica 80, pages 93-99.
Crossref
Crossref
Glen B. Baker & Ronald T. Coutts. (1989) Metabolism of monoamine oxidase inhibitors. Progress in Neuro-Psychopharmacology and Biological Psychiatry 13:3-4, pages 395-403.
Crossref
Crossref
M. Sandler & V. Glover. 1989. Drugs for the Treatment of Parkinson’s Disease. Drugs for the Treatment of Parkinson’s Disease
411
431
.
J. S. Fowler, A. P. Wolf, R. R. MacGregor, S. L. Dewey, J. Logan, D. J. Schlyer & B. Langstrom. (2006)
Mechanistic Positron Emission Tomography Studies: Demonstration of a Deuterium Isotope Effect in the Monoamine Oxidase‐Catalyzed Binding of [
11
C]l‐Deprenyl in Living Baboon Brain
. Journal of Neurochemistry 51:5, pages 1524-1534.
Crossref
Crossref
É. Szökő, H. Kalász, Á. György, J. Pucsok, K. Magyar & J. Knoll. (1988) Metabolism of (-)deprenyl and its structural analogues. Pharmacological Research Communications 20, pages 143-144.
Crossref
Crossref
T.S. Rao, G.B. Baker & R.T. Coutts. (1987) N, N-dipropargyl-2-phenylethylamine, a potential prodrug of 2-phenylethylamine: Neurochemical and neuropharmacological studies in rat. Brain Research Bulletin 19:1, pages 47-55.
Crossref
Crossref
Angela M. Mayne & Peter J. Evans. (1987) Fate of the monoamine oxidase inhibitor pargyline in cultured hepatocytes. Biochemical Pharmacology 36:14, pages 2289-2295.
Crossref
Crossref